Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment

BACKGROUND: Crizotinib is an approved tyrosine kinase inhibitor in the treatment of advanced-stage non-small-cell lung cancer patients with anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement. Renal dysfunction after crizotinib administration was recently reported, but the physiopatholo...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Case Rep Oncol
Hoofdauteurs: Rosoux, Adeline, Duplaquet, Fabrice, Ocak, Sebahat
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: S. Karger AG 2017
Onderwerpen:
Case Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5567074/
https://ncbi.nlm.nih.gov/pubmed/28868009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000475755
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items